Voters in North Dakota sent a clear message that health care decisions, from pregnancy to end-of-life care, must involve only patients and their physicians.
Cliffhangers can be really annoying if you care about the ending. So to resolve Monday's cliffhanger . . . IVF will continue in North Dakota.
Don't infringe on women's health. This was the message that voters in North Dakota sent yesterday through their rejection of Measure 1, a "right to life" amendment that, if passed, would have also ended IVF and other infertility services in the state. Because of vague language, adoption of the measure could also have affected end-of-life and palliative care.
The final tally: 64% of voters rejected the measure, with 36% supporting it.
“Today, North Dakota voters decided that they do not want government intervening in their most personal medical decisions from pregnancy to end-of-life,” said Karla Rose Hanson, spokeswoman for the North Dakotans Against Measure 1 coalition, in a quote to Inforum.
How genetic variables impact oral contraceptive use and VTE risk
March 27th 2024A comprehensive study delved into the interplay of polygenic and hereditary factors in venous thromboembolism risk among oral contraceptive users, shedding light on potential genetic markers for refined risk assessment and counseling.
Read More
Recap on reproductive rights with David Hackney, MD, MS
December 20th 2022In this episode of Pap Talk, we spoke with David Hackney, MD, MS, maternal-fetal medicine physician at Case Western Reserve University and chair of ACOG's Ohio chapter for a full recap of where restrictions on reproductive rights have been and where they're going.
Listen
In this episode of Pap Talk, Gloria Bachmann, MD, MSc, breaks down what it means to be a health care provider for incarcerated individuals, and explores the specific challenges women and their providers face during and after incarceration. Joined by sexual health expert Michael Krychman, MD, Bachmann also discusses trauma-informed care and how providers can get informed.
Listen
Unveiling the complexities of preterm birth risk from nativity, ethnicity, and race
March 22nd 2024A recent study dissected the relationships between maternal nativity, ethnicity, and race in influencing preterm birth rates, shedding light on disparities and suggesting avenues for future research.
Read More
Dostarlimab shows significant survival benefits in endometrial cancer trial
March 21st 2024GlaxoSmithKline's phase 3 trial demonstrated promising overall and progression-free survival outcomes in patients with primary advanced or recurrent endometrial cancer, paving the way for potential FDA approval.
Read More